<DOC>
	<DOCNO>NCT02868801</DOCNO>
	<brief_summary>The purpose study evaluate Efficacy safety pregabalin sustain release tablet versus placebo postherpetic neuralgia .</brief_summary>
	<brief_title>Efficacy Safety Pregabalin Sustained Release Tablet Postherpetic Neuralgia</brief_title>
	<detailed_description>This randomize , double-blind , multicenter , placebo-controlled trial compare efficacy safety pregabalin SR v placebo patient PHN . The study conduct 27 study center China . Patients randomize receive pregabalin , start 165 mg/day increase maintenance dose 330 660 mg/day , placebo . The study include 1-week , single-blind , placebo run-in period ; 2-week dose-escalation/optimization phase ; 12-week , fixed-dose treatment period ; 1-week taper phase .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>1 . Outpatient ，Patients stay hospital overnight； 2 . Patients must pain present 3 month heal herpes zoster skin rash； 3 . At least 4 day least 8 pain diary ( Pain Numeric Rating Scale ) must complete satisfactorily within seven day singleblind , placebo runin period , average pain score must great equal 4； 4 . At screen ( V0 ) enrollment ( V1 ) , patient must score great equal 40 mm 100 mm pain visual analog scale； 5 . Women neither pregnant lactating , childbearing age confirm negative serum pregnancy test baseline practice appropriate method contraception throughout study . 1 . Decrease ≥30 % pain VAS ≥ 4 two pain diary placebo runin period . ( order remove potential placeboresponders ) ； 2 . Patients fail respond previous treatment PHN gabapentin dose ≥1200 mg/day ； 3 . History use pregabalin participation previous trial pregabalin； 4 . Patients skin condition severe nonPHN pain might impair self assessment pain cause PHN； 5 . Patients Nervous system disorder might impair complete pain diary sleep interference diaries； 6 . History epilepsy treat drug therapy； 7 . Previous surgical therapy PHN； 8 . History use effective therapy 2 week screen ( V0 ) , eg : acupuncture moxibustion , Transcutaneous Electrical Nerve Stimulation； 9 . Potentially retinal toxicity drug past now； 10 . Prohibited medication without appropriate washout； 11 . Malignancy within past 2 years； 12 . Laboratory examination : WBC＜2.5×109/L；ANC＜1.5×109/L；PLT＜100×109/L；ALT/AST＞3ULN； 13 . Creatinine clearance ≤ 60 mL/min； 14 . Positive antibody Hepatitis c，Human immunodeficiency virus ，Treponema pallidum ； 15 . Patients allergic intolerant pregabalin drug similarly chemical structure ； 16 . History illicit drug alcohol abuse within last 2 years； 17 . Clinically significant unstable hepatic , respiratory , hematologic illness psychologic condition ; unstable cardiovascular disease may increase risk participation clinical trial opinion study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Pregabalin</keyword>
</DOC>